Minimal residual disease in thyroid carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Surgical Pathology

Background:

• Disseminated tumor cells (DTCs) in differentiated (DTC) and medullary thyroid carcinomas (MTC) are a key research area.
• Immunocytochemistry and PCR are used to detect rare cancer cells in blood and lymph nodes.
• Thyroid-specific markers (Tg mRNA, TPO mRNA) and tumor markers (telomerase, CK20) are investigated for detection.

Purpose of the Study:

• To evaluate molecular detection methods for disseminated tumor cells in thyroid cancer.
• To compare the sensitivity of molecular techniques with traditional methods like immunohistochemistry.
• To explore the potential of these methods for early detection and risk stratification.

Main Methods:

• Reverse transcription polymerase chain reaction (RT-PCR) for detecting specific mRNA markers (Tg, TPO, CK20).
• Quantitative PCR systems to prevent false-positive results.
• Analysis of blood samples and fine-needle aspiration (FNA) biopsies.
• Comparison of CK20 RT-PCR with immunohistochemistry for lymph node assessment.

Main Results:

• Thyroid-specific and tumor-specific markers were detected in blood and FNA samples from thyroid cancer patients.
• CK20 RT-PCR identified a higher percentage of lymph node involvement compared to immunohistochemistry.
• Quantitative PCR was established to improve accuracy and avoid false positives.

Conclusions:

• Molecular detection of DTCs, particularly using CK20 RT-PCR, offers enhanced sensitivity for identifying tumor cell dissemination.
• These methods may aid in refining risk groups for tailored surgical or adjuvant therapies.
• Further large-scale, prospective studies are needed to confirm the prognostic value of minimal residual disease (MRD) in thyroid carcinoma.